No actionable trading signal. This is a routine voting rights notification with no impact on fundamentals, guidance, or capital structure. Monitor next earnings release or material event for directional cues.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 1 $50.66entry
- T+1 · 3mo ago −0.43%α −0.88% · $50.44
- T+5 · 2mo ago −4.01%α −4.09% · $48.63
- T+20 · 7w ago −3.93%α −5.11% · $48.67
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK filed a routine Total Voting Rights notification under UK Disclosure Guidance and Transparency Rule 5.6.1R, disclosing its issued share capital as of 31 August 2026. The filing confirms 4,316,302,379 ordinary shares outstanding, with 270,881,064 held in treasury, resulting in 4,045,421,315 voting rights. This is a standard administrative disclosure with no material financial or operational impact.
Key Facts
- Issued share capital as of 31 August 2026: 4,316,302,379 ordinary shares of 31.25 pence each.
- Treasury shares: 270,881,064.
- Total voting rights: 4,045,421,315.
- Filing is a routine monthly disclosure under FCA DTR 5.6.1R.
Financial Impact
No financial impact, routine administrative disclosure.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (GSK), Batch item 1 | 0001654954-26-008044 |
| Document: 0001654954-26-008044-index-headers.html | 0001654954-26-008044 |
| Document: 0001654954-26-008044-index.html | 0001654954-26-008044 |
| Document: 0001654954-26-008044.txt | 0001654954-26-008044 |
| 6-K Filing (GSK), Batch item 5 | 0001654954-26-008044 |
| Document: 0001654954-26-008044-index-headers.html | 0001654954-26-008044 |
| Document: 0001654954-26-008044-index.html | 0001654954-26-008044 |
| Document: 0001654954-26-008044.txt | 0001654954-26-008044 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers